ClinicalTrials.gg
CompletedNCT01976091Updated Jun 15, 2023Results posted

A Gene Transfer Therapy Study to Evaluate the Safety of SRP-9004 (Patidistrogene Bexoparvovec) in Participants With Limb-Girdle Muscular Dystrophy, Type 2D (LGMD2D)

A Phase 1/2 interventional study of SRP-9004 in Limb-Girdle Muscular Dystrophy, Type 2D, sponsored by Sarepta Therapeutics, Inc.. Completed. Open to participants aged 7 Years and older. Per ClinicalTrials.gov, last updated 2023-06-15.

Sponsored by Sarepta Therapeutics, Inc. · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
6
Allocation
Non-randomized
Ages
7 Years and older
Sex
All
01

Study summary

This is an open-label, dose escalation gene transfer therapy study evaluating the safety of SRP-9004 (patidistrogene bexoparvovec) via isolated limb infusion (ILI) administration in approximately 6 participants with LGMD2D.

02

Conditions studied

  • Limb-Girdle Muscular Dystrophy, Type 2D

Keywords

  • limb girdle muscular dystrophy
  • LGMD2D
  • alpha-sarcoglycan
  • gene transfer
  • adeno-associated virus
03

In context

Muscular Dystrophies, Limb-Girdle

47 studies on the registry are indexed under Muscular Dystrophies, Limb-Girdle; 10 are open to participants now.

This study's enrollment of 6 is below the median of 13 across 22 interventional studies indexed under Muscular Dystrophies, Limb-Girdle.

Browse Muscular Dystrophies, Limb-Girdle studies →

Lead sponsor

Sarepta Therapeutics, Inc. is the lead sponsor of 52 studies on the registry; 8 are open to participants now.

Of its 21 completed or terminated interventional studies of FDA-regulated products, 12 (57%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
7 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Cohort 1A must be adult and wheelchair-dependent; Cohorts 1B and 2 will be participants of age 7 or older.
  • Confirmed alpha-sarcoglycan deficiency or identified sarcoglycan alpha (SGCA) deoxyribonucleic acid (DNA) mutation.
  • Participants enrolled in Cohorts 1B or 2 must be able to walk independently, but must exhibit signs of lower extremity weakness (that is, a Gowers' sign, use a handrail for climbing stairs) and walk ≤80% of predicted distance on the 6 minute walk test (6MWT) based on normative data.

Key Exclusion Criteria:

  • Active viral infection based on clinical observations.
  • The presence of SGCA mutations without weakness or loss of function.
  • Symptoms or signs of cardiomyopathy.
  • Serological evidence of (HIV), , or C infection.
  • Diagnosis of (or ongoing treatment for) an disease.
  • Participants with AAVrh74 or AAV8 binding antibody titers ≥ 1:50 as determined by enzyme-linked immunosorbent assay (ELISA) immunoassay.

Other inclusion/exclusion criteria apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    Cohort 1A: SRP-9004 Low Dose (Single Limb Perfusion)

    Non-ambulant participants with LGMD2D will receive 1 low dose of SRP-9004 via ILI to a single limb on Day 0.

    Genetic: SRP-9004

  • Experimental
    Cohort 1B Low Dose (Bilateral Limb Perfusion)

    Participants with LGMD2D will receive 1 low dose of SRP-9004 via ILI to both limbs on Day 0.

    Genetic: SRP-9004

  • Experimental
    Cohort 2 High Dose (Bilateral Limb Perfusion)

    Participants with LGMD2D will receive 1 high dose of SRP-9004 via ILI to both limbs on Day 0.

    Genetic: SRP-9004

Interventions

  • GeneticSRP-9004

    Isolated Limb Infusion (ILI)

    Also known as: patidistrogene bexoparvovec

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs).

    An AE is defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered study drug related. An AE was considered serious if, in the view of the investigator or sponsor, it resulted in any of the following outcomes: death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, or a congenital anomaly/birth defect. Treatment-related Treatment Emergent Adverse Event (TEAE) is defined as an TEAE that was classified by the investigator as related to treatment.

    Time frame: Up to 2 Years

Secondary outcomes

  1. Change From Baseline of the Distance Walked in 6 Minutes (6MWT)

    The 6MWT was performed by standardized procedures for all participants. Participants were asked to walk a set course in 6 minutes (timed), and the distance walked (in meters) was recorded.

    Time frame: Baseline, Up to 2 Years

07

Results

Posted Apr 1, 2022

Participant flow

Participant flow — Overall Study
MilestoneCohort 1A: SRP-9004Cohort 1B: SRP-9004Cohort 2: SRP-9004
Started132
Received at least 1 dose of study drug132
Completed132
Not completed000

Outcome measures

PrimaryNumber of Participants With Adverse Events (AEs).

An AE is defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered study drug related. An AE was considered serious if, in the view of the investigator or sponsor, it resulted in any of the following outcomes: death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, or a congenital anomaly/birth defect. Treatment-related Treatment Emergent Adverse Event (TEAE) is defined as an TEAE that was classified by the investigator as related to treatment.

Time frame:
Up to 2 Years
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs).
ParticipantsCohort 1A: SRP-9004Cohort 1B: SRP-9004Cohort 2: SRP-9004
Adverse Events132
Serious Adverse Events021
Treatment Related TEAEs132
SecondaryChange From Baseline of the Distance Walked in 6 Minutes (6MWT)

The 6MWT was performed by standardized procedures for all participants. Participants were asked to walk a set course in 6 minutes (timed), and the distance walked (in meters) was recorded.

Time frame:
Baseline, Up to 2 Years
Reported as:
Mean · Meters
Change From Baseline of the Distance Walked in 6 Minutes (6MWT)
MetersCohort 1A: SRP-9004Cohort 1B: SRP-9004Cohort 2: SRP-9004
Change From Baseline of the Distance Walked in 6 Minutes (6MWT)NA ± NA-66.0 ± 77.7829.0 ± NA

Adverse events

Collected over Baseline up to 2 Years. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1A: SRP-90040/1 (0%)0/1 (0%)1/1 (100%)
Cohort 1B: SRP-90040/3 (0%)2/3 (66.7%)3/3 (100%)
Cohort 2: SRP-90040/2 (0%)1/2 (50%)2/2 (100%)
Most frequent serious events
Most frequent serious events
EventCohort 1A: SRP-9004Cohort 1B: SRP-9004Cohort 2: SRP-9004
RhabdomyolysisMusculoskeletal and connective tissue disorders0/11/31/2
MyoglobinuriaRenal and urinary disorders0/10/31/2
Femur fractureInjury, poisoning and procedural complications0/11/30/2
Most frequent other events
Showing 10 of 55
Most frequent other events
EventCohort 1A: SRP-9004Cohort 1B: SRP-9004Cohort 2: SRP-9004
RashSkin and subcutaneous tissue disorders1/10/30/2
Back painMusculoskeletal and connective tissue disorders1/10/31/2
Procedural painInjury, poisoning and procedural complications0/13/32/2
FatigueGeneral disorders0/11/32/2
Pain in extremityMusculoskeletal and connective tissue disorders0/10/32/2
Catheter site haematomaGeneral disorders0/12/30/2
InsomniaPsychiatric disorders0/10/31/2
HypoaesthesiaNervous system disorders0/11/31/2
Upper respiratory tract infectionInfections and infestations0/11/31/2
Viral infectionInfections and infestations0/11/31/2

Baseline characteristics

The full analysis set (FAS) included all participants who received at least 1 administration of SRP-9004 during the study.

Age, Continuous
Age, Continuous(Years)Cohort 1A: SRP-9004Cohort 1B: SRP-9004Cohort 2: SRP-9004Total
Mean49 ± NA10 ± 2.6510 ± 2.8316.5 ± 16.06
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1A: SRP-9004Cohort 1B: SRP-9004Cohort 2: SRP-9004Total
Female1012
Male0314
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1A: SRP-9004Cohort 1B: SRP-9004Cohort 2: SRP-9004Total
Hispanic or Latino0000
Not Hispanic or Latino1326
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1A: SRP-9004Cohort 1B: SRP-9004Cohort 2: SRP-9004Total
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White1326
More than one race0000
Unknown or Not Reported0000
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Mendell JR, Chicoine LG, Al-Zaidy SA, Sahenk Z, Lehman K, Lowes L, Miller N, Alfano L, Galliers B, Lewis S, Murrey D, Peterson E, Griffin DA, Church K, Cheatham S, Cheatham J, Hogan MJ, Rodino-Klapac LR. Gene Delivery for Limb-Girdle Muscular Dystrophy Type 2D by Isolated Limb Infusion. Hum Gene Ther. 2019 Jul;30(7):794-801. doi: 10.1089/hum.2019.006. Epub 2019 Apr 19. PubMed 30838895 ↗
  • Mendell JR, Rodino-Klapac LR, Rosales XQ, Coley BD, Galloway G, Lewis S, Malik V, Shilling C, Byrne BJ, Conlon T, Campbell KJ, Bremer WG, Taylor LE, Flanigan KM, Gastier-Foster JM, Astbury C, Kota J, Sahenk Z, Walker CM, Clark KR. Sustained alpha-sarcoglycan gene expression after gene transfer in limb-girdle muscular dystrophy, type 2D. Ann Neurol. 2010 Nov;68(5):629-38. doi: 10.1002/ana.22251. PubMed 21031578 ↗
  • Mendell JR, Rodino-Klapac LR, Rosales-Quintero X, Kota J, Coley BD, Galloway G, Craenen JM, Lewis S, Malik V, Shilling C, Byrne BJ, Conlon T, Campbell KJ, Bremer WG, Viollet L, Walker CM, Sahenk Z, Clark KR. Limb-girdle muscular dystrophy type 2D gene therapy restores alpha-sarcoglycan and associated proteins. Ann Neurol. 2009 Sep;66(3):290-7. doi: 10.1002/ana.21732. PubMed 19798725 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2015 to primary completion in Mar 2019, 49 months.

Results were first posted in Apr 2022, 3 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2013
First posted
Nov 5, 2013
StartActual
Feb 1, 2015
Primary completionActual
Mar 14, 2019
CompletionActual
Mar 14, 2019
Results first posted
Apr 1, 2022
Last update
Jun 15, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01976091
Responsible party
Sponsor
First posted
Nov 5, 2013
Start date
Feb 1, 2015
Primary completion
Mar 14, 2019
Completion
Mar 14, 2019
Results posted
Apr 1, 2022
Last update
Jun 15, 2023

Study contacts

Medical Director
study director · Sarepta Therapeutics, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion